Hematological Interventions in NICU Care: The Use of rEpo, IVIG, and rG-CSF

Clinics in Perinatology

Volumn 39, Issue 1, 2012, Pages 177-190

  Christensen, Robert D ^a,b  

^a INTERMOUNTAIN HEALTHCARE   (United States)

^b McKay Dee Hospital Center   (United States)

Author keywords

IVIG; NICU; REPO; RG CSF

Indexed keywords

ANTIBIOTIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACIDOSIS; ADJUVANT THERAPY; ANEMIA; BONE MARROW DEPRESSION; CANDIDA; COAGULASE NEGATIVE STAPHYLOCOCCUS; CYTOPENIA; ERYTHROCYTE TRANSFUSION; ESCHERICHIA COLI; HOSPITAL INFECTION; HUMAN; HYPOXIC ISCHEMIC ENCEPHALOPATHY; LUNG DYSPLASIA; NECROTIZING ENTEROCOLITIS; NEUROPROTECTION; NEUTROPENIA; NEWBORN INFECTION; NEWBORN INTENSIVE CARE; NEWBORN MORTALITY; NEWBORN SEPSIS; NONHUMAN; PRIORITY JOURNAL; RETICULOCYTE COUNT; RETROLENTAL FIBROPLASIA; REVIEW; SEPTIC SHOCK; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS AGALACTIAE; THROMBOCYTOPENIA; VERY LOW BIRTH WEIGHT;

ERYTHROPOIETIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC DISEASES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INFECTION; INTENSIVE CARE UNITS, NEONATAL; NEUROPROTECTIVE AGENTS; RECOMBINANT PROTEINS;

EID: 84857071873     PISSN: 00955108     EISSN: 15579840     Source Type: Journal    
DOI: 10.1016/j.clp.2011.12.005     Document Type: Review

References (81)

1. Testa U. Erythropoietic stimulating agents. Expert Opin Emerg Drugs 2010, 15:119-138.
2. Song S., Long S.R., Marder W.E., et al. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa. Ann Pharmacother 2009, 43:1203-1210.
3. Warwood T.L., Ohls R.K., Lambert D.K., et al. Intravenous administration of darbepoetin to NICU patients. J Perinatol 2006, 26:296-300.
4. Warwood T.L., Ohls R.K., Lambert D.K., et al. Urinary excretion of darbepoetin after intravenous vs. subcutaneous administration to preterm neonates. J Perinatol 2006, 26:636-639.
5. Warwood T.L., Ohls R.D., Wiedmeier S.E., et al. Single-dose darbepoetin administration to anemic preterm neonates. J Perinatol 2008, 25:725-730.
6. Ohlsson A., Aher S.M. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006, 3. CD004863.
7. Baer V.L., Lambert D.K., Henry E., et al. Among very-low-birth-weight neonates is red blood cell transfusion an independent risk factor for subsequently developing a severe intraventricular hemorrhage?. Transfusion 2011, 51:1170-1178.
8. Baer V.L., Lambert D.K., Henry E., et al. Red blood cell transfusion of preterm neonates with a Grade 1 intraventricular hemorrhage is associated with extension to a Grade 3 or 4 hemorrhage. Transfusion 2011, 51:1933-1939.
9. Christensen R.D., Lambert D.K., Baer V.L., et al. Postponing or eliminating red blood cell transfusions of very low birth weight neonates by obtaining all baseline laboratory blood tests from otherwise discarded fetal blood in the placenta. Transfusion 2011, 51:253-258.
10. Donadee C., Raat N.J., Kanias T., et al. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation 2011, 124:465-476.
11. Reynolds J.D., Ahearn G.S., Angelo M., et al. S-nitrosohemoglobin deficiency: a mechanism for loss of physiological activity in banked blood. Proc Natl Acad Sci U S A 2007, 104:17058-17062.
12. Ballabh P. Intraventricular hemorrhage in premature infants: mechanism of disease. Pediatr Res 2010, 67:1-8.
13. Bell E.F., Strauss R.G., Widness J.A., et al. Randomized trial of liberal versus restrictive guidelines for red blood cell transfusion in preterm infants. Pediatrics 2005, 115:1685-1691.
14. McCoy T.E., Conrad A.L., Richman L.C., et al. Neurocognitive profiles of preterm infants randomly assigned to lower or higher hematocrit thresholds for transfusion. Child Neuropsychol 2011, 17:347-367.
15. Nopoulos P.C., Conrad A.L., Bell E.F., et al. Long-term outcome of brain structure in premature infants: effects of liberal vs restricted red blood cell transfusions. Arch Pediatr Adolesc Med 2011, 165:443-450.
16. Tempera A., Stival E., Piastra M., et al. Early erythropoietin influences both transfusion and ventilation need in very low birth weight infants. J Matern Fetal Neonatal Med 2011, 24:1060-1064.
17. Aher S., Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006, 3. CD004868.
18. Christensen R.D. Association between red blood cell transfusions and necrotizing enterocolitis. J Pediatr 2011, 158:349-350.
19. Christensen R.D., Lambert D.K., Henry E., et al. Is "transfusion-associated necrotizing enterocolitis" an authentic pathogenic entity?. Transfusion 2010, 50:1106-1112.
20. Josephson C.D., Wesolowski A., Bao G., et al. Do red cell transfusions increase the risk of necrotizing enterocolitis in premature infants?. J Pediatr 2010, 157:972-978. e1-3.
21. Blau J., Calo J.M., Dozor D., et al. Transfusion related acute gut injury: necrotizing enterocolitis in very low birth weight neonates following packed red blood cell transfusion. J Pediatr 2011, 158:403-409.
22. El-Dib M., Narang S., Lee E., et al. Red blood cell transfusion, feeding and necrotizing enterocolitis in preterm infants. J Perinatol 2011, 31:183-187.
23. Gordon P.V. What progress looks like in NEC research. J Perinatol 2011, 31(3):149.
24. Warwood T.L., Lambert D.K., Henry E., et al. Very low birth weight infants qualifying for a 'late' erythrocyte transfusion: does giving darbepoetin along with the transfusion counteract the transfusion's erythropoietic suppression?. J Perinatol 2011, 31(Suppl 1):S17-S21.
25. Li Y., Juul S.E., Morris-Wiman J.A., et al. Erythropoietin receptors are expressed in the central nervous system of mid-trimester human fetuses. Pediatr Res 1996, 40:376-380.
26. Juul S.E., Harcum J., Li Y., et al. Erythropoietin is present in the cerebrospinal fluid of neonates. J Pediatr 1997, 130:428-430.
27. Juul S.E., Anderson D.K., Li Y., et al. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res 1998, 43:40-49.
28. Juul S.E., Yachnis A.T., Christensen R.D. Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 1998, 52:235-249.
29. Juul S.E., Yachnis A.T., Rojiani A.M., et al. Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr Dev Pathol 1999, 2:148-158.
30. Sola A., Rogido M., Lee B.H., et al. Erythropoietin after focal cerebral ischemia activates the Janus kinase-signal transducer and activator of transcription signaling pathway and improves brain injury in postnatal day 7 rats. Pediatr Res 2005, 57:481-487.
31. Juul S.E., Beyer R.P., Bammler T.K., et al. Microarray analysis of high-dose recombinant erythropoietin treatment of unilateral brain injury in neonatal mouse hippocampus. Pediatr Res 2009, 65:485-492.
32. Juul S.E., McPherson R.J., Bauer L.A., et al. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics 2008, 122:383-391.
33. Juul S.E., McPherson R.J., Bammler T.K., et al. Recombinant erythropoietin is neuroprotective in a novel mouse oxidative injury model. Dev Neurosci 2008, 30:231-242.
34. McPherson R.J., Juul S.E. Recent trends in erythropoietin-mediated neuroprotection. Int J Dev Neurosci 2008, 26:103-111.
35. Sola A., Peng H., Rogido M., et al. Animal models of neonatal stroke and response to erythropoietin and cardiotrophin-1. Int J Dev Neurosci 2008, 26:27-35.
36. Sola A., Wen T.C., Hamrick S.E., et al. Potential for protection and repair following injury to the developing brain: a role for erythropoietin?. Pediatr Res 2005, 57(5 Pt 2):110R-117R.
37. Bierer R., Roohi M., Peceny C., et al. Erythropoietin increases reticulocyte counts and maintains hematocrit in neonates requiring surgery. J Pediatr Surg 2009, 44:1540-1545.
38. Bishara N., Ohls R.K. Current controversies in the management of the anemia of prematurity. Semin Perinatol 2009, 33:29-34.
39. Bierer R., Peceny M.C., Hartenberger C.H., et al. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics 2006, 118:e635-e640.
40. Ohls R.K., Ehrenkranz R.A., Das A., National Institute of Child Health and Human Development Neonatal Research Network, et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics 2004, 114:1287-1291.
41. Ohls R.K., Dai A. Long-acting erythropoietin: clinical studies and potential uses in neonates. Clin Perinatol 2004, 31:77-89.
42. Inder T.E., Clemett R.S., Austin N.C., et al. High iron status in very low birth weight infants is associated with an increased risk of retinopathy of prematurity. J Pediatr 1997, 131:541-544.
43. Slusarski J.D., McPherson R.J., Wallace G.N., et al. High-dose erythropoietin does not exacerbate retinopathy of prematurity in rats. Pediatr Res 2009, 66:625-630.
44. McPherson R.J., Juul S.E. Erythropoietin for infants with hypoxic-ischemic encephalopathy. Curr Opin Pediatr 2010, 22:139-145.
45. Ohlsson A., Lacy J.B. Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst Rev 2004, 1. CD000361.
46. Shah P.S., Kaufman D.A. Antistaphylococcal immunoglobulins to prevent staphylococcal infection in very low birth weight infants. Cochrane Database Syst Rev 2009, 2. CD006449.
47. Figueras-Aloy J., Rodríguez-Miguélez J.M., Iriondo-Sanz M., et al. Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease. Pediatrics 2010, 125:139-144.
48. DeJonge M., Burchfield D., Bloom B., et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 2007, 151:260-265.
49. Weisman L.E., Thackray H.M., Steinhorn R.H., et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics 2011, 128:271-279.
50. Ohlsson A., Lacy J. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev 2010, 3. CD001239.
51. Brocklehurst P., INIS Collaborative Group Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med 2011, 365:1201-1211.
52. Christensen R.D., Brown M.S., Hall D.S., et al. Effect on neutrophil kinetics and serum opsonic capacity of intravenous administration of immune globulin to neonates with clinical signs of early-onset sepsis. J Pediatr 1991, 118:606-614.
53. Harper T.E., Christensen R.D., Rothstein G., et al. Effect of intravenous immunoglobulin G on neutrophil kinetics during experimental group B streptococcal infection in neonatal rats. Rev Infect Dis 1986, 8(Suppl 4):S401-S408.
54. Harper T.E., Christensen R.D., Rothstein G. The effect of administration of immunoglobulin to newborn rats with Escherichia coli sepsis and meningitis. Pediatr Res 1987, 22:455-460.
55. Lassiter H.A., Christensen R.D., Parker C.J. Immunologic regulation of E. coli K1 by serum from neonatal rats is enhanced following intraperitoneal administration of human IgG. J Infect Dis 1989, 159:518-525.
56. Redd H., Christensen R.D., Fischer G.W. Circulating and storage neutrophils in septic neonatal rats treated with immune globulin. J Infect Dis 1988, 157:705-712.
57. Lassiter H.A., Christensen R.D., Parker C., et al. Neutrophil-mediated killing, opsonization, and serum-mediated killing of Escherichia coli K1 by neonatal rats. Biol Neonate 1988, 53:156-162.
58. Lassiter H.A., Robinson T.W., Brown M.S., et al. Effect of intravenous immunoglobulin G on the deposition of immunoglobulin G and C3 onto type III group B streptococcus and Escherichia coli K1. J Perinatol 1996, 16:346-351.
59. Alcock G.S., Liley H. Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. Cochrane Database Syst Rev 2002, 3. CD003313.
60. Maheshwari A., Christensen R.D., Calhoun D.A. Immune-mediated neutropenia in the neonate. Acta Paediatr Suppl 2002, 91(438):98-103.
61. Desenfants A., Jeziorski E., Plan O., et al. Intravenous immunoglobulins for neonatal alloimmune neutropenia refractory to recombinant human granulocyte colony-stimulating factor. Am J Perinatol 2011, 28:461-466.
62. Rayment R., Brunskill S.J., Soothill P.W., et al. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst Rev 2011, 5. CD004226.
63. Crawford J., Armitage J., Balducci L., National Comprehensive Cancer Network, et al. Myeloid growth factors. J Natl Compr Canc Netw 2009, 7:64-83.
64. Satwani P., Morris E., van de Ven C., et al. Dysregulation of expression of immunoregulatory and cytokine genes and its association with the immaturity in neonatal phagocytic and cellular immunity. Biol Neonate 2005, 88:214-227.
65. Dale D.C., Bonilla M.A., Davis M.W., et al. A randomized, controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 1993, 81:2496-2502.
66. Bonilla M.A., Gillio A.P., Ruggeiro M., et al. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med 1989, 320:1574-1580.
67. Cairo M., Suen Y., Knoppel E., et al. Decreased G-CSF and IL-3 production and gene expression from mononuclear cells of newborn infants. Pediatr Res 1992, 31:574-578.
68. Schibler K., Leichty K., White W., et al. Production of granulocyte colony-stimulating factor in vitro by monocytes from-preterm and term neonates. Blood 1993, 82:2479-2484.
69. Leichty K., Schibler K., Ohls R., et al. The failure of newborn mice infected with Escherichia coli to accelerate neutrophil production correlates with their failure to increase transcripts for granulocyte colony-stimulating factor and interleukin-6. Biol Neonate 1993, 64:331-340.
70. Cairo M., Plunkett J., Mauss D., et al. Seven-day administration of recombinant granulocyte colony-stimulating factor to newborn rats: modulation of neonatal neutrophilia, myelopoiesis, and group B streptococcal sepsis. Blood 1990, 76:1788-1794.
71. Cairo M.S., van de Ven C., Mauss D., et al. Modulation of neonatal rat myeloid kinetics resulting in peripheral neutrophilia by single pulse administration of Rh granulocyte-macrophage colony-stimulating factor and Rh granulocyte colony-stimulating factor. Biol Neonate 1991, 59:13-21.
72. Gillan E.R., Christensen R.D., Suen Y., et al. A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia. Blood 1994, 84:1427-1433.
73. Cairo M.S., Christensen R.D., Sender L.S., et al. Results of a phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in very low birthweight neonates: significant induction of circulatory neutrophils, monocytes, platelets, and bone marrow neutrophils. Blood 1995, 86:2509-2515.
74. Cairo M.S., Agosti J., Ellis R., et al. A randomized, double-blind, placebo-controlled trial of prophylactic recombinant human granulocyte-macrophage colony-stimulating factor to reduce nosocomial infections in very low birth weight neonates. J Pediatr 1999, 134:64-70.
75. Carr R., Brocklehurst P., Dore C., et al. Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomized controlled trial. Lancet 2009, 373:226-233.
76. Kuhn P., Messer J., Paupe A., et al. A multicentre, randomized, placebo-controlled trial of prophylactic recombinant granulocyte colony stimulating factor in preterm neonates with neutropenia. J Pediatr 2009, 155:324-330.
77. Carr R. Is there a role for GM- or G-CSF and immunoglobulins in the prevention and treatment of neonatal sepsis?. Neonatology 2011, 100:338. (A).
78. Carr R., Modi N., Dore C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst Rev 2003, 3. CD003066.
79. Walkovich K., Boxer L.A. Congenital neutropenia in a newborn. J Perinatol 2011, 31(Suppl 1):S22-S23.
80. Dale D.C., Welte K. Cyclic and chronic neutropenia. Cancer Treat Res 2011, 157:97-108.
81. Calhoun D.A., Christensen R.D., Edstrom C.S., et al. Consistent approaches to procedures and practices in neonatal hematology. Clin Perinatol 2000, 27:733-753.